Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Melanoma 92Neoplasms 82Colorectal Neoplasms 62Squamous Cell Carcinoma of Head and Neck 61Neoplasm Metastasis 58Triple Negative Breast Neoplasms 49Carcinoma, Renal Cell 47Breast Neoplasms 38Lung Neoplasms 36Ovarian Neoplasms 32Pancreatic Neoplasms 30Head and Neck Neoplasms 29Stomach Neoplasms 28Urinary Bladder Neoplasms 26Carcinoma, Transitional Cell 26Parkinson Disease 4, Autosomal Dominant Lewy Body 23Endometrial Neoplasms 23Uterine Cervical Neoplasms 21Carcinoma, Hepatocellular 18Recurrence 15Esophageal Neoplasms 15Prostatic Neoplasms 14Lymphoma 14Carcinoma, Squamous Cell 12Small Cell Lung Carcinoma 11Kidney Neoplasms 11Cholangiocarcinoma 11Advanced Solid Tumor 11Solid Tumor 10

Interventions

pembrolizumab 1Poly I-C 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Recurrence, Local × pembrolizumab × Clear all
NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago

Phase 1 Recruiting
36 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡